Chronic adaptive versus conventional DBS response patterns in Parkinson's disease: A pilot randomized crossover trial

Jun Tanimura[1,3,✉], **Takehiro Yako**[2], **and Takao Hashimoto**[1]

[1]Department of Neurology, Aizawa Hospital, 2-5-1 Honjo, Matsumoto, Nagano 390-0814, Japan
[2]Department of Neurosurgery, Aizawa Hospital, 2-5-1 Honjo, Matsumoto, Nagano 390-0814, Japan
[3]Present address: Emory National Primate Research Center, Emory University, 954 Gatewood Road NE, Atlanta, GA 30329

***Background*: Adaptive deep brain stimulation (aDBS) modulates stimulation based on real-time biomarkers, potentially offering advantages over conventional DBS (cDBS). Clinical evidence under chronic stimulation remains limited. *Objectives*: To compare aDBS versus cDBS efficacy in patients with Parkinson's disease (PD) under chronic stimulation and examine baseline-dependent patterns of treatment response. *Methods*: This was a pilot, double-blind, randomized crossover trial in nine PD patients with bilateral subthalamic nucleus DBS. Patients underwent consecutive one-month periods of cDBS and aDBS after a four-month postoperative interval. aDBS used a dual-threshold algorithm adjusting amplitude based on subthalamic beta-band LFP power. Primary outcomes were daily ON/OFF durations and dyskinesia duration under optimized medication. Mixed-effects ANCOVA estimated treatment effects. Bayesian analyses integrated prior evidence to assess probabilities of clinically meaningful differences. Exploratory analyses examined treatment-by-modifier interactions. *Results*: No statistically significant differences emerged between treatments. Directional effects varied: ON duration favored cDBS, while troublesome dyskinesia and UPDRS scores favored aDBS. Bayesian analyses indicated low probabilities that these differences reached clinical importance (29.4% probability for cDBS advantage on ON time, 7.5% for aDBS advantage on UPDRS Part III). Substantial between-patient heterogeneity was observed. Exploratory analyses suggested higher baseline disease burden enhanced cDBS advantages for motor fluctuations and aDBS advantages for motor severity, though modification effects varied across outcome–baseline combinations. *Conclusions*: aDBS and cDBS showed comparable population-level efficacy. Patient-specific baseline characteristics may influence treatment advantages for specific outcomes. These findings warrant larger trials to identify patient subgroups who may benefit from each stimulation approach under the current form of adaptive stimulation.**

Adaptive deep brain stimulation | conventional deep brain stimulation | Parkinson's disease | randomized crossover trial | motor fluctuations

Correspondence: ***tanimura.jun@gmail.com***

Introduction

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for Parkinson's disease (PD), being particularly beneficial for patients who experience motor fluctuations or medication-induced dyskinesias[1-4]. Conventional DBS (cDBS) provides continuous stimulation at a fixed amplitude, whereas adaptive DBS (aDBS) modulates the stimulation amplitude in real-time, guided by physiological biomarkers such as local field potential (LFP) activity recorded directly from implanted electrodes[5-7]. The aDBS approach, particularly utilizing STN beta-band oscillations (~13–30 Hz) peak power amplitude as biomarkers, is based on foundational studies demonstrating their relationship with motor symptoms such as bradykinesia and rigidity[8-12]. The rationale for the use of aDBS is to maintain symptom control while reducing unnecessary stimulation, conserving battery life, and potentially minimizing side effects[13].

Despite this promising rationale, clinical evidence supporting the use of aDBS over cDBS under chronic stimulation remains limited[13]. Pioneering studies with well-controlled exploratory designs consistently demonstrated that aDBS resulted in better motor outcomes[14,15]. However, more real-world-oriented follow-up studies, which carefully eliminated perioperative acute-lesion effects or assessed patients under anti-parkinsonian medication, showed no difference in motor outcomes when aDBS was compared to cDBS[16,17], whereas aDBS was suggested to have advantages in dyskinesia score improvement over cDBS[17]. Recent trials[18-20] have provided important advances in evaluating chronic aDBS, including extended follow-up periods and diverse trial designs. However, the issue remains unsettled regarding comparative efficacy of aDBS and cDBS due to limited evidence under fully blinded conditions over chronic treatment periods.

Furthermore, optimal patient selection criteria for aDBS have yet to be established[21]. Although a recent Delphi consensus reached agreement that patients with pronounced motor fluctuations and dyskinesias are most likely to benefit from adaptive stimulation[21], clinical evidence from long-term, blinded studies remains limited. Given individual variations in disease characteristics and outcome priorities, identifying how baseline clinical characteristics influence aDBS response would be important for personalized treatment selection.

In this study, we assessed the clinical efficacy of aDBS versus cDBS in patients with PD using a double-blind, randomized, crossover study design. We used a clinically available dual-threshold aDBS algorithm that continuously adjusted stimulation amplitude according to beta-band LFP activity power in the STN. To ensure assessment under stable chronic condi-

DRAFT



Fig. 1. Participant flow: randomized two-period crossover. Flow diagram showing numbers screened, randomized, allocated to each first-period sequence, completed, and analyzed, with exclusions and reasons specified at each stage; recruitment and assessment windows are indicated.

tions, evaluations were performed after a postoperative stabilization period of more than four months and after one month of each stimulation method (in random order) under optimized antiparkinsonian medication. Subsequently, we conducted exploratory, hypothesis-generating analyses examining how patient-specific baseline characteristics modify the relative treatment advantages between aDBS and cDBS.

Methods

Study Design and Participants

We conducted a pilot, two-period, double-blind, crossover randomized controlled trial comparing adaptive DBS (aDBS) with conventional DBS (cDBS) in patients with Parkinson's disease (Figure 1). The trial employed a 1:1 allocation ratio and aimed to assess treatment differences between the two stimulation modes. The primary analysis was designed to estimate treatment differences, followed by hypothesis-generating exploratory analyses examining baseline-dependent effect modification of comparative treatment response across outcomes between aDBS and cDBS.

Eligible participants were patients with a clinical diagnosis of Parkinson's disease, aged under 75 years, with motor complications (motor fluctuations and/or dyskinesia). We excluded patients with cognitive impairment (MMSE < 24), or with significant psychiatric symptoms requiring treatment changes. All participants were recruited from the Movement Disorders Clinic at Aizawa Hospital, Matsumoto, Japan. The study was registered with the UMIN Clinical Trials Registry (UMIN000058937).

Sample Size

As a pilot study, a formal sample-size calculation for the primary outcomes (ON/OFF time and dyskinesia duration) was not conducted; no previous studies had reported effect-size estimates required for a power calculation at the time we designed this trial[14-17]. Instead, we referred to secondary motor outcomes that had been evaluated in prior aDBS–cDBS trials. In particular, differences in UPDRS Part III scores between aDBS and cDBS were detected with 8–10 study participants[14,15]. Similarly, improvements in dyskinesia scores (Unified Dyskinesia Rating Scale, UDyRS) were detected with approximately 10 participants[17]. Based on these precedents, we aimed to recruit 10–12 participants to evaluate potential treatment differences.

DBS lead implantation surgery

All patients received standard bilateral STN implantation using the Percept PC system (Medtronic, USA), which enables both cDBS and aDBS. Bilateral lead implantation was performed in a single operative session. We implanted Medtronic 3387 leads under microelectrode guidance with local anesthesia. Prior to surgery, MRI (including heavy T2-weighted, proton, and gradient echo planar T1 sequences with gadolinium enhancement; MAGNETOM Avanto, Siemens Healthineers, Erlangen, Germany) and non-contrast CT scans were obtained with Leksell G Frame to plan target trajectories using Leksell Surgiplan (Elekta, Stockholm, Sweden). Recording tracks proceeded from anterodorsal to posteroventral at 20–30° from vertical and from lateral to medial at 20° from the sagittal plane. The STN borders were defined physiologically and fitted to atlas maps reconstructed from the Schaltenbrand and Bailey Atlas[22]. Lateral distance to the midline was measured on intraoperative CT scan. We targeted placement of the lowest electrode contact 0–1 mm below the ventral STN border and 10–11 mm lateral to midline, with final electrode locations confirmed by postsurgical MRI. The implantable pulse generator (IPG) was placed subcutaneously in the chest 2–3 days after lead implantation.

Stimulation setting

First, cDBS stimulation settings were made with monopolar stimulation, with the default setting of pulse duration 60 μs and frequency 130 Hz. The stimulation amplitude was initially determined by gradually increasing the amplitude day by day and was set just below that producing persistent adverse effects. Patients received cDBS therapy for the first three months after surgery. During the fourth month after surgery, which was one month prior to randomization, we configured the settings for aDBS and tested tolerance for aDBS stimulation over that month.

In this study, we used a clinically available dual-threshold aDBS algorithm that continuously adjusted stimulation amplitude within a programmed range according to beta-band LFP activity power in the STN. We followed the Clinician Programmer Guide[23,24] to set parameters for aDBS. First, we observed LFP with stimulation OFF to define (1) a contact pair to sense the large beta-band peak, which stands out sharply from the background activity; (2) a stimulating contact for monopolar stimulation; and (3) the range of LFP (Hz) to track (fixed to a 5 Hz range). We targeted a peak within 8–30 Hz with a peak amplitude of > 1.2 μV[23,24]. We searched for suitable sensing contacts bilaterally and finally chose one ipsilateral contact pair for the bilateral control. Next, LFP threshold values were configured for the

DRAFT

Dual Threshold Mode. During the process, the stimulation current was used as an actuator to capture two LFP-power thresholds[23,24]: first, patients received the highest amplitude just below that producing persistent adverse effects (upper therapeutic limit current), and the observed beta power during this stimulation was defined as the lower LFP threshold; subsequently, patients received a lower amplitude (fixed at 20% below the upper therapeutic limit current), and the observed beta power during this stimulation was defined as the upper LFP threshold. (Note that this latter approach for defining the upper LFP threshold deviates from the guidance[23,24]; this fixed 20% reduction—rather than using a level guided by the minimal current needed for symptom improvement—was adopted because, in our experience, it is often difficult to determine the threshold for the initial appearance of parkinsonian symptom improvement reliably.)

Finally, we defined the stimulation setting for aDBS: the higher stimulation current level was set as the upper therapeutic limit used during the LFP-threshold determination process, and the lower stimulation current level was fixed at 20% below the higher level. The ramp time, which is the time of changing between the two stimulation amplitudes, was set to 2.5 min for the upward direction and 5 min for the downward direction. After setting the aDBS program, the setting for cDBS current amplitude was also updated to use the same upper therapeutic limit. The patients entered the randomized crossover periods after confirmation of stable condition for a one-month aDBS period. During the one-month pre-randomization aDBS period, patients underwent 1–2 adjustment sessions to optimize the dual-threshold parameters. Throughout the titration periods, no changes to sensing or stimulation contacts were required.

Randomization and Integrity of the Blinding

An independent statistician prepared 12 opaque, sealed envelopes containing treatment sequence assignments. Four months after DBS implantation, personnel not involved in patient assessment or data analysis randomly selected and opened one envelope to determine the treatment sequence for each participant. Participants were assigned to receive either cDBS followed by aDBS (Sequence 1) or aDBS followed by cDBS (Sequence 2), with each treatment period lasting one month (Figure 1). Both participants and outcome assessors remained blinded throughout the study. Device programming was performed by independent, unblinded personnel who were not involved in outcome assessments. All analyses were conducted only after completion of all blinded assessments. Participants were not systematically asked which stimulation mode they believed they received.

Outcomes

Clinical outcomes were assessed at the end of each one-month treatment period. Baseline ("preoperative") values for all outcomes were obtained during an inpatient admission within 7 days prior to DBS implantation. Primary outcomes were daily ON time, OFF time, and dyskinesia duration (troublesome and non-troublesome), based on diary records averaged over the 7-day diary period. Secondary outcomes included total UPDRS score, individual UPDRS subscales (Parts I, II, III, IV), Mini-Mental State Examination (MMSE), Parkinson's Disease Questionnaire-39 (PDQ-39), and Schwab and England Activities of Daily Living (ADL) Scale. All motor assessments during crossover phases were performed in the medication-ON state with optimized medication.

Variable	Median [IQR] or N (%)
Female, n (%)	4 (44.4%)
Male, n (%)	5 (55.6%)
Age, y	62 (54–65)
Disease duration, y	10 (8–11)
LEDD, mg/day	932 (881–1182)
ADL (Schwab & England), %	90 (90–100)
Hoehn & Yahr, ON	3 (1–3)
Hoehn & Yahr, OFF	4 (4–4)
UPDRS Part I	1 (0–2)
UPDRS Part II, ON	3 (1–7)
UPDRS Part II, OFF	18 (17–27)
UPDRS Part III, ON	15 (3–18)
UPDRS Part III, OFF	37 (30–47)
UPDRS Part IV	8 (7–10)
UPDRS Total, ON	26 (13–34)
UPDRS Total, OFF	69 (56–86)
ON time, h/day	9.7 (8.0–10.1)
OFF time, h/day	8.3 (7.9–10.0)
Dyskinesia time troublesome, h/day	0.3 (0.1–1.7)
Dyskinesia time non-troublesome, h/day	1.8 (1.0–2.4)
MMSE	29 (28–30)
PDQ-39	45 (30–75)

Table 1. Patient demographics and clinical characteristics. Baseline demographic and clinical characteristics of the study participants at the preoperative assessment (n=9). UPDRS: Unified Parkinson's Disease Rating Scale; H&Y: Hoehn & Yahr stage; IQR: interquartile range; MMSE: Mini-Mental State Examination; PDQ-39: Parkinson's Disease Questionnaire; LEDD: levodopa-equivalent daily dose.

Statistical Analysis

Primary Analysis

We compared the efficacy of aDBS with that of cDBS. We used a mixed-effects ANCOVA model with fixed effects for treatment, period, sequence, and standardized baseline values, and subject-specific random intercepts estimated using REML, thereby explicitly modeling and quantifying between-patient variability while adjusting for design-related period and sequence effects, as well as baseline differences in the outcome measure assessed prior to surgery[25-27].

Treatment differences (aDBS minus cDBS) were estimated in original units as adjusted mean differences with 95% confidence intervals (CIs), accompanied by standardized effect sizes (Cohen's d). Cohen's d was calculated as the treatment estimate divided by the model residual standard deviation, which represents within-patient variability estimated for each outcome from the crossover design, enabling interpretation of effect size as the magnitude of treatment difference relative to natural within-patient variation. Confidence intervals for treatment estimates and Cohen's d were con-

DRAFT

structed using t-distribution critical values based on model degrees of freedom (Satterthwaite approximation). Cohen's d standard error was calculated using Hedges and Olkin's approximation for paired designs. All tests were two-sided with p-values adjusted for multiple comparisons using the Benjamini–Hochberg method. Time-based outcomes were analyzed on the log(1+x) scale to handle zero values, with back-transformation of marginal estimates and confidence intervals (via delta method) for presentation on the original time scale. We tested for differential carryover effects by comparing mixed models with and without a treatment-by-period interaction using likelihood-ratio tests (LRTs)[25,28,29]. Missing data were handled through available case analysis without imputation.

For clinical interpretation, we defined minimal clinically important differences (MCIDs) based on established thresholds: ± 2 hours/day for ON time[18,19]; ± 5 points for UPDRS Part III[30,31]; ± 8 points for UPDRS Total[30].

Sensitivity Analyses

To assess the robustness of our primary analysis, we conducted sensitivity analyses with two additional models: (1) a reduced ANCOVA model that excluded crossover-related terms (Period and Sequence) while retaining treatment effect, baseline adjustment, and random intercepts for patients; and (2) a crude paired comparison that computed treatment differences (aDBS–cDBS) without adjustment for baseline values, crossover structure, or between-patient variability. For both sensitivity models, we calculated treatment effect estimates and Cohen's d effect sizes with 95% confidence intervals using identical methods as the primary analysis.

Bayesian Complementary Analysis

For ON time and UPDRS Part III, we conducted Bayesian analyses integrating prior evidence from recent chronic aDBS trials with current data, enabling intuitive clinical interpretation through probabilistic assessment of treatment effects. These outcomes were selected for Bayesian analysis because (1) prior information on "aDBS versus cDBS" treatment effects was available from recent chronic aDBS trials[18,19], enabling construction of literature-informed prior distributions, and (2) established MCID thresholds exist for both outcomes[18,19,30,31]. We used the same model structure as the primary mixed-effects ANCOVA, estimating posterior distributions of treatment effects via Bayesian inference using Markov chain Monte Carlo (MCMC) sampling implemented in the `brms` package (version 2.21.0) in R, which uses Stan for MCMC computation.

We specified two prior distributions for the treatment effect coefficient (aDBS minus cDBS) as a sensitivity analysis. (1) Literature-informed priors were constructed as normal distributions based on recent chronic aDBS trials[18,19]: for ON time, prior = Normal(1.5, 3.0); for UPDRS Part III, prior = Normal(-3, 4). These priors reflect expectations of advantages of aDBS over cDBS on these outcomes based on prior evidence. Moderately wide standard deviations were used to appropriately incorporate this external evidence given methodological heterogeneity across trials (different device[19] or open-label design[18]). (2) Weakly informative priors used



Fig. 2. Distribution of clinical outcomes across study conditions. For each outcome, distributions at Preoperative, cDBS, and aDBS are shown (violin plots). Data from both randomization groups are pooled. Individual points are overlaid (jittered), and black diamonds indicate the median. H&Y: Hoehn & Yahr stage; UPDRS: Unified Parkinson's Disease Rating Scale; MMSE: Mini-Mental State Examination; PDQ-39: Parkinson's Disease Questionnaire; LEDD: levodopa-equivalent daily dose.

normal distributions centered at zero with moderate standard deviations (Normal(0, 4) for ON time; Normal(0, 6) for UPDRS Part III), representing minimal prior knowledge while reflecting realistic effect ranges. All other model parameters used default `brms` priors. For each outcome and prior specification, we ran four independent MCMC chains with 4000 iterations each (2000 warmup iterations discarded). Convergence was assessed using $\hat{R}$ statistics (< 1.01 indicating convergence) and effective sample sizes (all > 3400, indicating adequate precision for posterior inference).

We calculated: (1) posterior means and 95% credible intervals (CrIs), representing the range containing 95% of the posterior probability mass; and (2) probabilities of clinically meaningful effects, i.e., the probability that treatment differences exceed established MCID thresholds in each direction (favoring aDBS or cDBS).

Exploratory Analyses

DRAFT



Fig. 3. Treatment effects comparing aDBS and cDBS. Forest plot of treatment effect sizes (Cohen's d) with 95% confidence intervals. Blue indicates cDBS advantage; red indicates aDBS advantage. Gray dashed lines show conventional thresholds (0.2, 0.5, 0.8). Table displays absolute differences.

Exploratory analyses aimed to examine how the patient-specific baseline modifies the relative treatment advantages between aDBS and cDBS. Given the potential for heterogeneous treatment responses, we first quantified between-patient heterogeneity using the intraclass correlation coefficient (ICC)[32], equivalent to the intra-subject correlation coefficient[25], derived from the random intercept variance component of the mixed-effects ANCOVA model in the primary analysis. The ICC was calculated as $\mathrm{ICC} = \sigma_b^2/(\sigma_b^2 + \sigma^2)$, where σ_b^2 represents the between-patient variance and σ^2 the residual variance. Values were interpreted according to conventional thresholds[32], where ICC < 0.50, 0.50–0.75, 0.75–0.90, and > 0.90 indicate poor, moderate, good, and excellent reliability, respectively. In the present context, these categories describe the magnitude of between-patient heterogeneity, with higher ICC values indicating larger heterogeneity.

We then examined patterns of effect modification across outcomes based on baseline characteristics (modifiers) by fitting mixed-effects ANCOVA models including Treatment-by-Modifier interactions[33], with Period, Sequence, and z-scored baseline outcome values as covariates, and patient random intercepts. All baseline modifiers were z-scored and sign-aligned such that higher values indicated higher disease burden. Interaction effects were quantified using model-based correlation coefficients (r) derived from t-statistics via the transformation $r = t/\sqrt{t^2 + \mathrm{df}}$, with positive values indicating that higher baseline disease burden was associated with greater aDBS benefit relative to cDBS. Correlation coefficients were interpreted using reference thresholds: $|r| \geq 0.5$ indicating moderate-to-strong associations and $|r| \geq 0.8$ indicating strong associations. These analyses were explicitly exploratory and hypothesis-generating; thus no formal hypothesis tests were performed and no multiplicity adjustment was applied.

To verify the robustness of these exploratory estimates against influential outliers, we performed leave-one-out (LOO) sensitivity analyses, iteratively removing one patient and recalculating the partial correlation coefficients. We examined the range and sign consistency of r across all iterations. Each correlation coefficient was classified as non-robust if its sign reversed upon removal of any single participant. Only robust findings were considered for hypothesis generation and are emphasized in the Results and Figure 5 (non-robust findings shown as gray cells).

Analyses were performed using R version 4.3.1 with relevant packages including `lme4`, `lmerTest`, `emmeans`, and `brms`.

Study Registration and Ethics

The study was approved by the Ethics Committee of Aizawa Hospital (Approval No. 2020-064: R2-37) and conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent.

Results

Participants and Baseline Characteristics

Of 10 patients initially enrolled between January 2022 and January 2025, one withdrew due to psychological burden related to participation, leaving 9 patients who completed both randomized periods and were included in the final analysis (Figure 1). Participants were randomized to two sequences: Group 1 (n=5) received cDBS in Phase 1 followed by aDBS in Phase 2, while Group 2 (n=4) received aDBS in Phase 1 followed by cDBS in Phase 2. All 9 participants adhered to their assigned stimulation protocols throughout both one-month periods without protocol deviation. For each outcome, we analyzed all available observations (18 per measure, except MMSE with 15 observations).

Baseline characteristics are summarized in Table 1. The median age was 62 years (IQR 54–65) with a median disease duration of 10 years (IQR 8–11). Four participants (44.4%) were female. The median LEDD was 932 mg/day (IQR 881–1182), and the Hoehn & Yahr stage was 3 in the ON state (IQR 1–3) and 4 in the OFF state (IQR 4–4). Patients showed moderate to severe motor impairments, with median UPDRS Part III scores of 37 in the OFF state and 15 in the ON state. Motor complications were present in all participants (UPDRS Part IV median 8). Baseline time outcomes showed median daily ON time of 9.7 hours (IQR 8.0–10.1),

DRAFT



Posterior Mean [95% CrI] −1.40 hours/day [−3.55, 1.05]
Posterior Probability
Meaningful advantage on cDBS: P(❶) 29.4%
Meaningful advantage on aDBS: P(❷) 0.8%

Posterior Mean [95% CrI] −2.74 points [−6.11, 0.54]
Posterior Probability
Meaningful advantage on aDBS: P(❶) 7.5%
Meaningful advantage on cDBS: P(❷) 0.0%

Fig. 4. Treatment effect probabilities with clinical thresholds. Posterior probability distributions for treatment effects (aDBS–cDBS) from Bayesian mixed-effects crossover models for ON time and UPDRS Part III. Dashed vertical lines indicate minimal clinically important difference (MCID) thresholds (±2 hours/day for ON time, ±5 points for UPDRS Part III). Shaded regions indicate posterior probability mass favoring aDBS or cDBS that exceeds MCID thresholds. CrI: credible interval.

OFF time of 8.3 hours (IQR 7.9–10.0), troublesome dyskinesia time of 0.3 hours (IQR 0.1–1.7), and non-troublesome dyskinesia time of 1.8 hours (IQR 1.0–2.4).

Comparison of aDBS with cDBS

Figure 2 shows the distribution of clinical outcomes across preoperative, cDBS, and aDBS conditions. No differential carryover was detected for any outcome using likelihood-ratio tests (all $p \geq 0.105$, Supplementary Table S1).

The comparison of aDBS versus cDBS revealed heterogeneous treatment effect directions across clinical domains, with no statistically significant differences after adjusting for multiple comparisons (Figure 3). The ON time differed between treatments by 1.91 hours/day favoring cDBS (d = -0.94), which did not reach the prespecified minimal clinically important difference (MCID) of ±2 hours/day. Likewise, the OFF time differed between treatments by 0.73 hours/day favoring cDBS (d = -0.74). The duration of troublesome dyskinesias showed a small change favoring aDBS (-0.10 hours/day; d = 0.35). Both cDBS and aDBS reduced the total UPDRS score, with the reduction by aDBS exceeding that of cDBS by 5.93 points (95% CI -11.45 to -0.40, d = 1.20). However, this difference did not reach the 8-point minimal clinically important difference[30]. The reduction in UPDRS Part III scores also showed a larger reduction in the aDBS stimulation periods compared to the cDBS stimulation periods (d = 0.87), with an estimated difference of -2.68 points (95% CI -6.12 to 0.77), which did not reach the MCID of -5 points[30,31]. Other outcomes showed smaller or mixed effects as detailed in Figure 3. In summary, no statistically significant differences emerged across all outcomes, and treatment differences remained below MCID thresholds for outcomes with established MCIDs (ON time, UPDRS scores), suggesting similarity in population-level clinical effectiveness between aDBS and cDBS.

Sensitivity analyses demonstrated high consistency with the primary findings across all outcomes (Supplementary Table S2 and Supplementary Figure S1). The direction and magnitude of estimated aDBS–cDBS differences and effect sizes remained consistent regardless of model specification, with the reduced ANCOVA generally yielding estimates closer to the full ANCOVA than the crude approach. These findings confirm that our primary conclusion of similarity in population-level clinical effectiveness between aDBS and cDBS is robust to model specification.

Bayesian Complementary Findings

For ON time and UPDRS Part III, we conducted Bayesian analyses integrating prior evidence from recent trials with current data, providing intuitive clinical interpretations that directly address the probability of clinically meaningful treatment differences (Figure 4, Supplementary Table S3).

The posterior mean treatment effects (aDBS minus cDBS) were -1.40 hours/day (95% CrI -3.55 to 1.05) for ON time and -2.74 points (95% CrI -6.11 to 0.54) for UPDRS Part III. For ON time, the Bayesian estimate was stabilized compared to the frequentist estimate of -1.91 hours/day (95% CI -4.10 to 0.28), reflecting incorporation of prior information favoring aDBS. For UPDRS Part III, Bayesian and frequentist estimates were comparable (frequentist: -2.68 points, 95% CI -6.12 to 0.77). Probabilities of clinically meaningful treatment differences were low for both ON time (29.4% for cDBS advantage exceeding the -2 hours/day MCID) and UPDRS Part III (7.5% for aDBS advantage exceeding the -5 points MCID), suggesting similarity in population-level clinical effectiveness. Sensitivity analyses using weakly informative priors demonstrated that posterior estimates appropriately responded to prior specifications while maintaining consistent directional conclusions.

Exploratory Analyses: Predictors of aDBS Benefit

Between-Patient Heterogeneity

We first evaluated the between-patient variability using the mixed-effects ANCOVA model (see Methods). The median ICC was 0.67 (IQR 0.50–0.86), indicating moderate-to-substantial between-patient heterogeneity: after adjusting for baseline of the same outcome, sequence, and period, approximately 67% of the remaining modeled variance is attributable to differences between patients rather than within-patient variation (Supplementary Table S4)[32]. This supports the use of the mixed-effects framework and suggests that baseline clinical characteristics may shape treatment response.

Effect Modification Analysis

We examined Treatment-by-Modifier interactions for hypothesis generation, exploring baseline-dependent patterns in the comparative effects of aDBS and cDBS across outcomes (Figure 5; Supplementary Tables S5, S6). Leave-one-out sensitivity analyses of all 192 outcome–baseline combinations revealed that 84 (44%) showed robust patterns, which are displayed in color in Figure 5, while non-robust findings are shown as gray cells.

DRAFT



Fig. 5. Exploratory effect-modifier analysis: heatmap of model-based correlation coefficients. Correlation coefficients ((r) showing how baseline disease burden modifies relative treatment response. Red indicates aDBS advantage under higher burden; blue indicates cDBS advantage. Gray cells show non-robust findings. All analyses exploratory and hypothesis-generating.

Among robust correlations, outcome-specific directional patterns emerged. For motor fluctuation outcomes, higher baseline disease burden consistently predicted cDBS advantages for ON time (all 7 robust correlations) and predominantly for OFF time (7 of 9). For example, worse baseline PDQ-39 (r = -0.88), longer disease duration (r = -0.56), and higher UPDRS Part IV (r = -0.55) all correlated with ON-time benefits from cDBS. Troublesome dyskinesia showed consistent cDBS advantages with higher burden (3 of 3), while non-troublesome dyskinesia showed uniform aDBS advantages (10 of 10). For motor severity, UPDRS Part III and Total scores predominantly showed aDBS advantages with higher baseline burden (75–86% of robust correlations). Notably, higher baseline UPDRS Part IV correlated with larger Part III improvements under aDBS (r = 0.73), though Part IV outcomes themselves favored cDBS under higher burden (6 of 7). Quality-of-life (PDQ-39) improvements uniformly favored aDBS with higher burden, while cognitive outcomes (MMSE) predominantly favored cDBS.

Adverse Events

During the assessment after each one-month treatment period, none of the patients reported adverse events (such as paresthesia, dysarthria, dysphagia, etc.). Furthermore, no signs of device-related infections, cerebral hemorrhage, or seizures were observed or reported.

Discussion

Key findings

In this pilot, double-blind crossover trial, we observed no statistically significant differences between aDBS and cDBS. Directional patterns emerged: ON times tended to be longer and OFF times shorter with cDBS, while aDBS showed trends toward benefits for troublesome dyskinesias and UPDRS scores. Bayesian analyses integrating prior evidence indicated low probabilities of clinically meaningful differences (29.4% for ON time, 7.5% for UPDRS Part III), indicating similarity in population-level effectiveness between the two DBS modes. Hypothesis-generating exploratory analyses revealed substantial between-patient heterogeneity and suggested that higher baseline disease burden predicted cDBS advantages for motor fluctuations and aDBS advantages for motor severity outcomes.

Comparison with recent literature

Our findings contribute to emerging evidence on chronic aDBS therapy. Three recent trials have now evaluated aDBS over extended periods in real-world conditions. The ADAPT-PD trial[18] evaluated 68 patients using the same Percept PC device over 10 months, demonstrating good tolerability with 91% meeting performance thresholds (maintaining ON time within 2 hours/day of their cDBS baseline performance). Open-label comparison suggested modest improvements with dual-threshold aDBS (ON time +1.3 h/day, UPDRS Part III -2.6 points). Busch et al.[20] reported real-world outcomes in 8 patients with the same device, showing improved overall well-being and enhanced general movement on aDBS in an open-label design. Isaias et al.[19] conducted a double-blind crossover trial (2 weeks per mode) in 15 patients using a different device (AlphaDBS with a linear proportional algorithm for current-amplitude modulation) and found a trend favoring aDBS on UPDRS Part III (-4.14 points) and highly variable within-patient treatment response, with clinically meaningful improvements in 55% of patients for UPDRS Part III and 27% for ON time with aDBS compared with cDBS.

Our study extends this evidence with blinded randomization and longer chronic evaluation (1 month per mode). Treatment differences on UPDRS Part III were consistent across

DRAFT

trials (-2.68 points in our study, -2.6 in ADAPT-PD, -4.14 in Isaias et al.), but ON-time effects showed opposite directions (cDBS favored by +1.91 h/day in our study versus aDBS favored by +1.3 h/day in ADAPT-PD and +1.7 h/day in Isaias et al.). This directional discrepancy likely reflects substantial between-patient heterogeneity observed across studies (ICC = 0.67 in ours). Bayesian analysis accounting for this heterogeneity by integrating prior evidence showed low probabilities of meaningful population-level advantages (29.4% for cDBS on ON time, 7.5% for aDBS on UPDRS Part III), supporting comparable effectiveness between stimulation modes.

Of note, the ADAPT-PD trial rigorously compared dual-threshold (DT) and single-threshold (ST) aDBS algorithms in a randomized design and found no difference in the primary outcome, although exploratory analyses suggested somewhat greater improvements with DT than with ST relative to cDBS. These findings support our decision to focus exclusively on the DT algorithm in the present randomized, double-blind comparison against cDBS.

Interpretation and implications on effect modification analysis

Given substantial between-patient heterogeneity observed in prior studies and in ours, we explored how baseline clinical features modify relative treatment response patterns between aDBS and cDBS. In the robust associations that survived sensitivity analysis, higher baseline disease burden predicted cDBS advantages for motor fluctuation outcomes (ON time, OFF time), whereas it predicted aDBS advantages for motor severity outcomes (UPDRS Part III, Total scores). Notably, a similar dissociation across outcome domains was reported by Isaias et al.[19], who found that patients showing clinically meaningful improvement in ON time with aDBS were not necessarily the same individuals showing improvement in UPDRS Part III. Together, these patterns suggest that effect modification varies in an outcome-specific manner.

Our results partially converge with and diverge from Emura et al. (2025)[34]. They identified younger age as correlating with greater improvements in PDQ-39 and UPDRS Part II after transitioning to aDBS, whereas our analyses could not yield robust estimates for these associations. Similarly, they observed greater UPDRS Part IV improvement with higher baseline burden under aDBS, whereas our analyses suggested the opposite direction. These discrepancies likely reflect methodological differences—correlations of absolute change in a single-arm design versus randomized estimates of relative efficacy in a crossover trial—underscoring the hypothesis-generating nature of these analyses and their limited generalizability. Definitive identification of patient subgroups most likely to benefit from aDBS will require adequately powered trials designed specifically for subgroup analyses.

Recently highlighted physiological biomarkers such as beta bursts in dorsolateral STN or gamma oscillations in motor cortex[35-39] potentially offer advantages for alternative adaptive stimulation approaches through their specific associations with distinct outcomes, enabling more individualized treatment selection based on patient-specific treatment goals.

Limitations and generalizability

As a pilot study, the lack of formal sample size estimation in primary outcomes potentially limits the statistical power of our study, although it is comparable to previous aDBS clinical trials for our secondary outcome (UPDRS Part III)[14-17]. The wide confidence intervals in frequentist analysis and broader credible intervals in Bayesian posterior distributions reflect this limitation of statistical precision. We did not ask participants to guess their stimulation mode during the blinded periods, which would have further supported effective blinding. Each stimulation mode was blindly evaluated over a one-month period; although this duration exceeds that of other studies, it still limits inferences regarding further long-term efficacy or durability of treatment effects over months to years. The beta-band/clinical-symptom correspondence was not confirmed during the study, which may limit our interpretation in terms of the biomarker stability over our extended study period. The exploratory effect-modifier analyses are hypothesis-generating and require replication in larger trials. Our study used specific hardware (Percept PC) and LFP-based sensing with beta-band amplitude thresholding; thus, findings should be extrapolated cautiously to other biomarkers, algorithms, or devices. Device-level metrics (time at the higher stimulation amplitude, total energy delivered, battery consumption) were not prospectively collected. Some patient-centered outcomes such as sleep quality, non-motor symptoms, and patient preference for the two DBS modes were not systematically assessed during each stimulation period; future trials should include these endpoints to quantify any benefit of aDBS. Being a single-center study in Japan, external validity may be limited for settings with different healthcare systems, patient populations, or clinical practices in DBS management; thus, results should be interpreted with reference to our baseline patient characteristics and DBS programming methodology.

Conclusions

In this pilot randomized crossover trial, aDBS and cDBS showed no statistically significant differences across clinical outcomes, with low probabilities of clinically meaningful differences, together suggesting similarity in population-level effectiveness between the two DBS modes. Hypothesis-generating exploratory analyses revealed outcome-specific patterns, where higher baseline disease burden tended to predict cDBS advantages for motor fluctuations and aDBS advantages for motor severity outcomes, suggesting potential for individualized treatment selection based on patient-specific priorities. These findings support the view that aDBS and cDBS have comparable efficacy under chronic stimulation with optimized medication, and warrant confirmation in larger, multicenter trials designed to identify specific patient subgroups who may benefit from the current form of adaptive stimulation.

ACKNOWLEDGEMENTS

The authors thank Dr. Shoji Yomo for his contributions to surgical planning using the Surgiplan system, and Dr. Thomas Wichmann for his critical and constructive

DRAFT

comments on the manuscript.

FUNDINGS
This research received no external funding. All clinical procedures and routine follow-up were conducted as part of standard care at Aizawa Hospital and supported by institutional resources; no company provided financial or in-kind support.

COMPETING INTERESTS
Jun Tanimura has received honoraria from Eisai and FP Corporation outside of this work. Takehiro Yako and Takao Hashimoto declare no competing interests. The authors declare that there are no additional disclosures to report from the previous 12 months.

DATA AND CODE AVAILABILITY
All data and code are available through Harvard Dataverse (DOI:10.7910/DVN/U1SNWI).

GENERATIVE AI USAGE
The authors used ChatGPT (OpenAI), Claude (Anthropic), and Gemini (Google) to improve readability, grammar, word choice, and flow. After using these tools, the authors carefully reviewed and edited the content as needed and take full responsibility for the content of the published article.

AUTHOR CONTRIBUTIONS
Research project: A. Conception; B. Organization; C. Execution.
Statistical Analysis: A. Design; B. Execution; C. Review and Critique.
Manuscript Preparation: A. Writing of the first draft; B. Review and Critique.

Jun Tanimura (JT): 1A, 1B, 1C, 2A, 2B, 3A, 3B.
Takehiro Yako (TY): 1C, 3B.
Takao Hashimoto (TH): 1A, 1B, 2A, 2B, 2C, 3B.

REFERENCES

1. Follett, K.A., Weaver, F.M., Stern, M., Hur, K., Harris, C.L., Luo, P., Marks, W.J., Jr., Rothlind, J., Sagher, O., Moy, C., et al. (2010). Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease. N Engl J Med *362*, 2077–2091. 10.1056/NEJMoa0907083.

2. Okun, M.S., Gallo, B.V., Mandybur, G, Jagid, J., Foote, K.D., Revilla, F.J., Alterman, R., Jankovic, J., Simpson, R., Junn, F., et al. (2012). Subthalamic deep brain stimulation with a constant-current device in Parkinson's disease: an open-label randomised controlled trial. Lancet Neurol *11*, 140–149. 10.1016/S1474-4422(11)70308-8.

3. Perestelo-Perez, L., Rivero-Santana, A., Perez-Ramos, J., Serrano-Perez, P., Panetta, J., and Hilarion, P. (2014). Deep brain stimulation in Parkinson's disease: meta-analysis of randomized controlled trials. J Neurol *261*, 2051–2060. 10.1007/s00415-014-7254-6.

4. Schuepbach, W.M., Rau, J., Knudsen, K., Volkmann, J., Krack, P., Timmermann, L., Halbig, T.D., Hesekamp, H., Navarro, S.M., Meier, N., et al. (2013). Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med *368*, 610–622. 10.1056/NEJMoa1205158.

5. Beudel, M., and Brown, P. (2016). Adaptive deep brain stimulation in Parkinson's disease. Parkinsonism Relat Disord *22 Suppl 1*, S123–126. 10.1016/j.parkreldis.2015.09.028.

6. Habets, J.G.V., Heijmans, M., Kuijf, M.L., Janssen, M.L.F., Temel, Y., and Kubben, P.L. (2018). An update on adaptive deep brain stimulation in Parkinson's disease. Mov Disord *33*, 1834–1843. 10.1002/mds.115.

7. Stanslaski, S., Summers, R.L.S., Tonder, L., Tan, Y., Case, M., Raike, R.S., Morelli, N., Herrington, T.M., Beudel, M., Ostrem, J.L., et al. (2024). Sensing data and methodology from the Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) clinical trial. NPJ Parkinsons Dis *10*, 174. 10.1038/s41531-024-00772-5.

8. Kuhn, A.A., Kempf, F., Brucke, C., Doyle Gaynor, L., Martinez-Torres, I., Pogosyan, A., Trottenberg, T., Kupsch, A., Schneider, G.H., Hariz, M.I., et al. (2008). High-frequency stimulation of the subthalamic nucleus suppresses oscillatory beta activity in patients with Parkinson's disease in parallel with improvement in motor performance. J Neurosci *28*, 6165–6173. 10.1523/JNEUROSCI.0282-08.2008.

9. Kuhn, A.A., Kupsch, A., Schneider, G.H., and Brown, P. (2006). Reduction in subthalamic 8–35 Hz oscillatory activity correlates with clinical improvement in Parkinson's disease. Eur J Neurosci *23*, 1956–1960. 10.1111/j.1460-9568.2006.04717.x.

10. Ray, N.J., Jenkinson, N., Wang, S., Holland, P., Brittain, J.S., Joint, C., Stein, J.F., and Aziz, T. (2008). Local field potential beta activity in the subthalamic nucleus of patients with Parkinson's disease is associated with improvements in bradykinesia after dopamine and deep brain stimulation. Exp Neurol *213*, 108–113. 10.1016/j.expneurol.2008.05.008.

11. Weinberger, M., Mahant, N., Hutchison, W.D., Lozano, A.M., Moro, E., Hodaie, M., Lang, A.E., and Dostrovsky, J.O. (2006). Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol *96*, 3248–3256. 10.1152/jn.00697.2006.

12. Bergman, H., Wichmann, T., Karmon, B., and DeLong, M.R. (1994). The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol *72*, 507–520. 10.1152/jn.1994.72.2.507.

13. Little, S., and Brown, P. (2020). Debugging adaptive deep brain stimulation for Parkinson's disease. Mov Disord *35*, 555–561. 10.1002/mds.27996.

14. Little, S., Pogosyan, A., Neal, S., Zavala, B., Zrinzo, L., Hariz, M., Foltynie, T., Limousin, P., Ashkan, K., FitzGerald, J., et al. (2013). Adaptive deep brain stimulation in advanced Parkinson disease. Ann Neurol *74*, 449–457. 10.1002/ana.23951.

15. Little, S., Tripoliti, E., Beudel, M., Pogosyan, A., Cagnan, H., Herz, D., Bestmann, S., Aziz, T., Cheeran, B., Zrinzo, L., et al. (2016). Adaptive deep brain stimulation for Parkinson's disease demonstrates reduced speech side effects compared to conventional stimulation in the acute setting. J Neurol Neurosurg Psychiatry *87*, 1388–1389. 10.1136/jnnp-2016-313518.

16. Pina-Fuentes, D., van Dijk, J.M.C., van Zijl, J.C., Moes, H.R., van Laar, T., Oterdoom, D.L.M., Little, S., Brown, P., and Beudel, M. (2020). Acute effects of adaptive deep brain stimulation in Parkinson's disease. Brain Stimul *13*, 1507–1516. 10.1016/j.brs.2020.07.016.

17. Rosa, M., Arlotti, M., Marceglia, S., Cogiamanian, F., Ardolino, G., Di Fonzo, A., Lopiano, L., Scelzo, E., Merola, A., Locatelli, M., et al. (2017). Adaptive deep brain stimulation controls levodopa-induced side effects in Parkinsonian patients. Mov Disord *32*, 628–629. 10.1002/mds.26953.

18. Bronte-Stewart, H.M., Beudel, M., Ostrem, J.L., Little, S., Almeida, L., Ramirez-Zamora, A., Fasano, A., Hassell, T., Mitchell, K.T., Moro, E., et al. (2025). Long-term personalized adaptive deep brain stimulation in Parkinson disease: a nonrandomized clinical trial. JAMA Neurol *82*, 1171–1180. 10.1001/jamaneurol.2025.2781.

19. Isaias, I.U., Marceglia, S., Borellini, L., Mailland, E., Remore, L., Caffi, L., Palmisano, C., Bonvegna, S., Romito, L., Eleopra, R., et al. (2025). Safety and effectiveness of adaptive versus conventional deep brain stimulation in Parkinson's disease: a randomised, double-blind, crossover pilot trial. SSRN. http://dx.doi.org/10.2139/ssrn.5322545.

20. Busch, J.L., Kaplan, J., Behnke, J.K., Witzig, V.S., Drescher, L., Habets, J.G.V., and Kuhn, A.A. (2025). Chronic adaptive deep brain stimulation for Parkinson's disease: clinical outcomes and programming strategies. NPJ Parkinsons Dis *11*, 264. 10.1038/s41531-025-01124-7.

21. Guidetti, M., Bocci, T., De Pedro Del Alamo, M., Deuschl, G., Fasano, A., Martinez-Fernandez, R., Gasca-Salas, C., Hamani, C., Krauss, J.K., Kuhn, A.A., et al. (2025). Will adaptive deep brain stimulation for Parkinson's disease become a real option soon? A Delphi consensus study. NPJ Parkinsons Dis *11*, 110. 10.1038/s41531-025-00974-5.

22. Schaltenbrand, G., and Bailey, P. (1959). *Introduction to stereotaxis with an atlas of the human brain*. Stuttgart: Thieme.

23. Jimenez-Shahed, J. (2021). Device profile of the Percept PC deep brain stimulation system for the treatment of Parkinson's disease and related disorders. Expert Rev Med Devices *18*, 319–332. 10.1080/17434440.2021.1909471.

24. Medtronic (2020). Clinician programmer application for deep brain stimulation – clinician programming guide – Percept™ PC model B35200 neurostimulator – application version 2.0. Minneapolis, MN: Medtronic, Inc.

25. Byron Jones, M., and Kenward, M.G. (2014). *Design and Analysis of Cross-Over Trials*, 3rd ed. (Routledge).

26. Dwan, K., Li, T., Altman, D.G., and Elbourne, D. (2019). CONSORT 2010 statement: extension to randomised crossover trials. BMJ *366*, l4378. 10.1136/bmj.l4378.

27. Kenward, M.G., and Jones, B. (1987). The analysis of data from 2×2 cross-over trials with baseline measurements. Stat Med *6*, 911–926. 10.1002/sim.4780060806.

28. Li, B., Zhou, Z., Zhang, L., and Yang, Y. (2020). Testing treatment-by-period interaction in four-period crossover trials. Pharm Stat *19*, 145–163. 10.1002/pst.1975.

29. Schrag, A., Sampaio, C., Counsell, N., and Poewe, W. (2006). Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord *21*, 1200–1207. 10.1002/mds.20914.

DRAFT

30. Sanchez-Ferro, A., Matarazzo, M., Martinez-Martin, P., Martinez-Avila, J.C., Gomez de la Camara, A., Giancardo, L., Arroyo Gallego, T., Montero, P., Puertas-Martin, V., Obeso, I., et al. (2018). Minimal clinically important difference for UPDRS-III in daily practice. Mov Disord Clin Pract *5*, 448–450. 10.1002/mdc3.12632.

31. Koo, T.K., and Li, M.Y. (2016). A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med *15*, 155–163. 10.1016/j.jcm.2016.02.012.

32. Brankovic, M., Kardys, I., Steyerberg, E.W., Lemeshow, S., Markovic, M., Rizopoulos, D., and Boersma, E. (2019). Understanding of interaction (subgroup) analysis in clinical trials. Eur J Clin Invest *49*, e13145. 10.1111/eci.13145.

33. Emura, T., Tani, N., Hosomi, K., Kimoto, Y., Matsuhashi, T., Fujinaga, T., Miura, S., Fujita, Y., Mori, N., Khoo, H.M., et al. (2025). Adaptive deep brain stimulation benefits: younger patients with persistent wearing-off symptoms. Mov Disord Clin Pract. 10.1002/mdc3.70311.

34. Kehnemouyi, Y.M., Wilkins, K.B., Anidi, C.M., Anderson, R.W., Afzal, M.F., and Bronte-Stewart, H.M. (2021). Modulation of beta bursts in subthalamic sensorimotor circuits predicts improvement in bradykinesia. Brain *144*, 473–486. 10.1093/brain/awaa394.

35. Oehrn, C.R., Cernera, S., Hammer, L.H., Shcherbakova, M., Yao, J., Hahn, A., Wang, S., Ostrem, J.L., Little, S., and Starr, P.A. (2024). Chronic adaptive deep brain stimulation versus conventional stimulation in Parkinson's disease: a blinded randomized feasibility trial. Nat Med *30*, 3345–3356. 10.1038/s41591-024-03196-z.

36. Cernera, S., Oehrn, C.R., Hammer, L.H., Shcherbakova, M., Yao, J., Hahn, A., Wang, S., Ostrem, J.L., Little, S., and Starr, P.A. (2025). Sustained clinical benefit of adaptive deep brain stimulation in Parkinson's disease using gamma oscillations: a case report. Mov Disord *40*, 345–350. 10.1002/mds.30076.

37. Tinkhauser, G., Pogosyan, A., Little, S., Beudel, M., Herz, D.M., Tan, H., and Brown, P. (2017). The modulatory effect of adaptive deep brain stimulation on beta bursts in Parkinson's disease. Brain *140*, 1053–1067. 10.1093/brain/awx010.

38. Neumann, W.J., Gilron, R., Little, S., and Tinkhauser, G. (2023). Adaptive deep brain stimulation: from experimental evidence toward practical implementation. Mov Disord *38*, 937–948. 10.1002/mds.29415.

DRAFT